The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review.

Expert Rev Clin Immunol

Therapeutic Area Immunology & CNS, Boehringer Ingelheim International GmbH, Rheinland-Pfalz, Germany.

Published: March 2020

: Palmoplantar pustulosis (PPP) is a chronic, relapsing and refractory disease characterized by sterile pustules appearing on the palms and/or soles, accompanied by erythema, blistering, scales and/or keratinization. The overall burden of PPP in terms of its clinical impact, effect on patients and families, and economic consequences has not previously been investigated in a structured manner.: A structured search focused on identification of studies in PPP using specific search terms in PubMed and EMBASE® from 2005 onwards, with additional back-referencing and pragmatic searches. Outcomes of interest included clinical burden, humanistic burden, and economic burden.: In cross-sectional studies, approximately 75% of all PPP patients suffer from active disease, with risk of relapse remaining constant over time. Patients' health-related quality of life is significantly impaired, as expected for a disease affecting hands and feet. Tools have been described that assess the clinical as well as patient-reported burden of PPP; their performance in larger cohorts and/or clinical trials remains to be investigated. The key data limitations identified include inconsistent definitions for characterizing remission/relapse, and limited humanistic and economic burden data; future studies are required to address these evidence gaps.

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1708194DOI Listing

Publication Analysis

Top Keywords

economic burden
12
humanistic economic
8
palmoplantar pustulosis
8
burden ppp
8
burden
7
clinical
5
ppp
5
clinical humanistic
4
economic
4
burden palmoplantar
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!